基因组学视角下的组织细胞增生症发生与临床变异
本文综述了组织细胞增生症的基因组学研究进展。研究表明,反复发生的致癌突变将组织细胞增生症从原发性炎症性疾病重新定义为髓系肿瘤,其显著依赖异常的MAPK信号通路。新发现的遗传驱动因素与不同临床病理表型相关,且多种组织细胞增生症起源于造血干/祖细胞,突变前体细胞的分化阶段影响疾病范围与严重程度。
要点
- 组织细胞增生症是由单核、巨噬或树突状细胞克隆扩增所致的罕见血液病。
- 致癌突变及MAPK通路异常是核心机制,支持将其归为髓系肿瘤。
- 突变前体细胞分化阶段与疾病范围相关,激酶抑制剂对重症或难治患者有效。
核心结论
- 基因组学进展将组织细胞增生症重新定义为髓系肿瘤,显著依赖异常MAPK信号通路,并持续发现与临床病理表型相关的新遗传驱动因素。
- 多种组织细胞增生症起源于造血干/祖细胞,突变前体细胞的分化阶段是疾病范围与严重程度的重要但非唯一决定因素。
- 特定临床表现如神经退行性疾病可能源于影响卵黄囊来源组织驻留巨噬细胞的体细胞嵌合。
研究设计与样本
- 本文为综述,综合近期基因组学见解,探讨组织细胞增生症的发生与临床变异。
主要发现
- 反复发生的致癌突变将组织细胞增生症从原发性炎症性疾病重新定义为髓系肿瘤,显著依赖异常MAPK信号通路。
- 新遗传驱动因素不断被发现,许多改变与不同临床和病理表型相关。
- 在朗格汉斯细胞组织细胞增生症中,突变前体细胞的分化阶段被认为是疾病范围与严重程度的重要但非唯一决定因素。
- 特定临床表现如神经退行性疾病可能源于影响卵黄囊祖细胞来源组织驻留巨噬细胞的体细胞嵌合。
- 激酶抑制剂在重症或难治性疾病患者中显示强效活性。
临床怎么用
- 基因组学发现有助于优化组织细胞增生症的诊断、风险分层、疾病监测和治疗。
- 对重症或难治性疾病患者,激酶抑制剂显示强效活性。
局限性
- 本文为综述,未报告原始研究的具体样本量、阈值或统计值。
- 文中指出仍存在未解决的问题和未来方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Histiocytic neoplasms are rare haematologic diseases characterised by clonal expansions of cells with a monocyte, macrophage or dendritic cell phenotype. Their clinical manifestations are diverse, ranging from indolent lesions to aggressive systemic disease. Over recent decades, advances in genomic profiling have transformed the biological understanding of these conditions. The discovery of recurrent oncogenic mutations has reframed histiocytoses from primary inflammatory disorders to myeloid neoplasms, with a notable dependence on aberrant mitogen-activated protein kinase (MAPK) signalling. Novel genetic drivers continue to be uncovered, with many alterations correlating with distinct clinical and pathological phenotypes. Parallel studies have refined the understanding of disease ontogeny, demonstrating that diverse histiocytoses originate from haematopoietic stem/progenitor cells. In Langerhans cell histiocytosis, the differentiation stage of the mutated precursor cell is considered an important - but not the sole - determinant of disease extent and severity. Additional evidence suggests that specific clinical manifestations, such as neurodegenerative disease, may result from somatic mosaicism affecting tissue-resident macrophages derived from yolk sac progenitors. Collectively, these findings refine histiocytosis diagnosis, risk stratification, disease monitoring and treatment, with robust activity of kinase inhibitors in patients with severe or refractory disease. In this review, we synthesise recent genomic insights into histiocytosis development and variation, while addressing remaining questions and future directions. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
引用
- Kemps PG, van Halteren AG, van Wezel T, et al. Histiocytosis development and clinical variation through the lens of genomics. J Pathol. 2026. PMID: 42200684. doi:10.1002/path.70081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。